Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105170 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00105170 is a Phase 1 study that was terminated before completion, run by Biogen. The registered enrollment target is 13 participants.
The verdict
NCT00105170, a Phase 1 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors. This is the first study of hCBE-11 in humans and is designed to determine the safety and how well patients tolerate this investigational drug. The study duration is two years with treatment visits occurring weekly for either 4 or 8 weeks, follow-up for 8 weeks and long-term follow-up contact every 3 months thereafter.
Interventions
- DRUG hCBE-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105170
The ClinicalTrials.gov registry entry for NCT00105170 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hCBE-11 is the first listed.
NCT00105170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105170 about?
NCT00105170 is a clinical study titled "Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors". This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors. This is the first study of hCBE-11 in humans and is designed to determine the safety and how well patients tolerate this investigational drug. The study duration is two years with treatment visits occurring ...
What is the current status of trial NCT00105170?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2005-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00105170?
The interventions under investigation include: hCBE-11 (DRUG).
Who is sponsoring clinical trial NCT00105170?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.